Human IGFBP-1 ELISA Kit PicoKine®

What it means: Target is the analyte this ELISA kit is designed to measure. The target shown here is IGFBP1.

How to interpret here: Treat IGFBP1 as the “what you will quantify” in your experiment. This listing shows reactivity as Human, which is your first check for species compatibility. The sample types (cell culture supernatants, serum, plasma (heparin, EDTA) and urine.) indicate which matrices are expected to work with minimal troubleshooting. The sensitivity (<1 pg/ml) helps you judge whether expected baseline levels are detectable. Choose this when your organism/matrix match and you can keep samples within the kit’s working range; consider another kit if you need different species validation, different matrices, or a different sensitivity/range profile.

Helpful naming notes:

• Synonyms to cross-check: Insulin-like growth factor-binding protein 1, IBP-1, IGF-binding protein 1, IGFBP-1, Placental protein 12, PP12 (use these to confirm you’re targeting the right biomarker in literature and databases).

Why it matters for buying:

• Biomarker match: Confirms you are measuring the analyte aligned to your hypothesis (family members/isoforms can lead to different biology).
• Study design: Target abundance can vary widely by tissue, treatment, and disease state—expect to optimize dilution and controls.
• Species fit: Reactivity Human reduces the risk of weak binding or under-recovery.
• Matrix fit: Listed matrices cell culture supernatants, serum, plasma (heparin, EDTA) and urine. are where the kit is expected to behave predictably.

How it impacts your workflow:

• Start with a dilution series: Run serial dilutions so readings fall in the linear region of the curve.
• Use matrix-appropriate controls: Include blanks, standards, and (when possible) a matrix-matched positive control or spike-in control.
• Validate your matrix: Perform spike recovery and dilution linearity (parallelism) before processing a full cohort.

What to watch out for:

• Cross-reactivity/isoforms: If specificity is critical, confirm datasheet cross-reactivity notes and consider orthogonal validation.
• Sample handling: Keep samples cold, minimize freeze–thaw cycles, and avoid repeated vortexing/foaming for fragile proteins.
• Near-limit measurements: Close to <1 pg/ml, small background shifts can change detectability—use replicates and consistent washing.

What it means: Reactivity indicates the species the kit is validated to detect. The reactivity shown here is Human.

How to interpret here: Use Human as your primary compatibility gate. This kit is intended to measure IGFBP1 within that species context. Pair it with sample type guidance (cell culture supernatants, serum, plasma (heparin, EDTA) and urine.) to pick matrices and controls. Choose this when your samples come from the listed species; validate carefully if you must use another species (spike recovery + parallelism) because sequence differences can reduce binding and distort quantification.

Why it matters for buying:

• Performance confidence: Species-matched reagents reduce weak signal and inaccurate quantification.
• Comparability: Avoid comparing absolute concentrations across species unless equivalent recovery is validated.
• Time and cost: Off-species use typically increases pilot work and repeat runs.

How it impacts your workflow:

• Cross-species QC: If you use another species, test spike recovery and dilution linearity in your exact matrix.
• Control strategy: Prefer species-matched positive controls and keep matrices consistent across groups.
• Interpretation discipline: Treat unexpected low values as potentially biological OR compatibility-related until validated.

What to watch out for:

• Do not assume cross-reactivity: Similar gene names across species do not guarantee binding equivalence.
• Matrix effects: Anticoagulants and lysis buffers can change background—keep conditions consistent.

What it means: Sample Type(s) lists the matrices this ELISA kit is intended/commonly used for. The listed sample types are cell culture supernatants, serum, plasma (heparin, EDTA) and urine..

How to interpret here: Treat cell culture supernatants, serum, plasma (heparin, EDTA) and urine. as “where this kit is expected to behave predictably.” Because reactivity is Human, your best results usually come from species- and matrix-matched samples. If you are working near the sensitivity (<1 pg/ml), matrix background becomes a key limiter—pilot testing is strongly recommended. Choose this if your matrix matches (or you can validate a new one); consider another kit if you require validated performance in a different matrix with minimal development work.

Why it matters for buying:

• Compatibility check: Unlisted matrices often require additional optimization and validation.
• Reproducibility: Matrix differences (serum vs plasma, anticoagulants, lysis buffers) can drive variability.
• Planning: Sample type affects prep steps (clarification, inhibitors), dilution strategy, and control selection.

How it impacts your workflow:

• Prep and clarify: Remove debris (centrifuge/filtration) and keep prep consistent across samples.
• Dilution series: Run serial dilutions to reduce interference and land in the linear curve region.
• Validate in your matrix: Use spike recovery and parallelism (dilution linearity) before full cohorts.

What to watch out for:

• Hemolysis/lipemia: Can increase background and mask true signal—clarify and consider extra dilution.
• Protease activity: Some targets degrade quickly—keep samples cold and use inhibitors where appropriate.
• Freeze–thaw: Repeated freeze–thaw can reduce recovery—aliquot samples when possible.

What it means: Sensitivity is the lowest concentration the assay can reliably distinguish from background under recommended conditions. The sensitivity shown here is <1 pg/ml.

How to interpret here: Use <1 pg/ml as a feasibility check for your expected baseline. If you expect IGFBP1 levels near this value, plan a pilot run and replicates. In matrices like cell culture supernatants, serum, plasma (heparin, EDTA) and urine., background can reduce practical sensitivity—validate matrix effects (spike recovery + parallelism). Species match (Human) also matters because mismatch can effectively worsen sensitivity. Choose this if expected concentrations are comfortably above the sensitivity; consider a more sensitive kit if your baseline is near the limit or your matrix is challenging.

Why it matters for buying:

• Low-abundance feasibility: Lower sensitivity values generally support detection of smaller amounts of analyte.
• Project risk: Near-limit work typically needs extra QC, replicates, and careful technique—factor into timelines and sample needs.
• Matrix reality: Practical sensitivity in real samples can be worse than buffer-based claims—plan validation.

How it impacts your workflow:

• Pilot near expected range: Use a dilution series to see where samples fall relative to the curve.
• Background control: Consistent washing, timing, and clean pipetting preserve low-level detection.
• QC checks: Spike recovery + parallelism help confirm reliability in your matrix.

What to watch out for:

• False “non-detects”: High background can mask low signals—optimize dilution and washing.
• Edge effects: Temperature gradients and plate drying increase noise—seal plates and keep workflow continuous.